Psoriasis Patients Satisfied with Biologics Save

A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy. (Citation Source http://buff.ly/1MpWMQg) 

The study included 426 psoriasis patients who were receiving methotrexate, cyclosporine, or an injectable biologic (adalimumab, etanercept, or ustekinumab), and classified as biologic experienced or biologic naïve. The treatment group comparisons are shown below:

Despite having more severe psoriasis, patients using biologics reported higher satisfaction with their treatment, which may positively affect outcomes. Reports of patient satisfaction with prior treatments and choices regarding dosing frequency, among all other considerations, should be evaluated in determining an appropriate biologic medication for psoriasis.